These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

981 related articles for article (PubMed ID: 23728671)

  • 1. Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus.
    Ronellenfitsch U; Schwarzbach M; Hofheinz R; Kienle P; Kieser M; Slanger TE; Jensen K;
    Cochrane Database Syst Rev; 2013 May; (5):CD008107. PubMed ID: 23728671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative chemo(radio)therapy versus primary surgery for gastroesophageal adenocarcinoma: systematic review with meta-analysis combining individual patient and aggregate data.
    Ronellenfitsch U; Schwarzbach M; Hofheinz R; Kienle P; Kieser M; Slanger TE; Burmeister B; Kelsen D; Niedzwiecki D; Schuhmacher C; Urba S; van de Velde C; Walsh TN; Ychou M; Jensen K
    Eur J Cancer; 2013 Oct; 49(15):3149-58. PubMed ID: 23800671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma.
    Tomita Y; Moldovan M; Chang Lee R; Hsieh AH; Townsend A; Price T
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD012078. PubMed ID: 33210731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer.
    Janmaat VT; Steyerberg EW; van der Gaast A; Mathijssen RH; Bruno MJ; Peppelenbosch MP; Kuipers EJ; Spaander MC
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD004063. PubMed ID: 29182797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemoradiotherapy versus chemoradiotherapy plus surgery for esophageal cancer.
    Vellayappan BA; Soon YY; Ku GY; Leong CN; Lu JJ; Tey JC
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD010511. PubMed ID: 28829911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular-targeted first-line therapy for advanced gastric cancer.
    Song H; Zhu J; Lu D
    Cochrane Database Syst Rev; 2016 Jul; 7(7):CD011461. PubMed ID: 27432490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative Chemoradiotherapy vs Chemotherapy for Adenocarcinoma of the Esophagogastric Junction: A Network Meta-Analysis.
    Ronellenfitsch U; Friedrichs J; Barbier E; Bass GA; Burmeister B; Cunningham D; Eyck BM; Grilli M; Hofheinz RD; Kieser M; Kleeff J; Klevebro F; Langley R; Lordick F; Lutz M; Mauer M; Michalski CW; Michl P; Nankivell M; Nilsson M; Seide S; Shah MA; Shi Q; Stahl M; Urba S; van Lanschot J; Vordermark D; Walsh TN; Ychou M; Proctor T; Vey JA
    JAMA Netw Open; 2024 Aug; 7(8):e2425581. PubMed ID: 39093560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or the gastroesophageal junction: A meta-analysis based on clinical trials.
    Zhao X; Ren Y; Hu Y; Cui N; Wang X; Cui Y
    PLoS One; 2018; 13(8):e0202185. PubMed ID: 30138325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant (postoperative) therapy for esophageal cancer.
    Ku GY; Ilson DH
    Thorac Surg Clin; 2013 Nov; 23(4):525-33. PubMed ID: 24199702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative chemotherapy for resectable thoracic esophageal cancer.
    Malthaner R; Fenlon D
    Cochrane Database Syst Rev; 2001; (1):CD001556. PubMed ID: 11279723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of overall and recurrence-free survival after neoadjuvant chemotherapy for gastroesophageal adenocarcinoma: Pooled analysis of individual patient data (IPD) from randomized controlled trials (RCTs).
    Ronellenfitsch U; Schwarzbach M; Hofheinz R; Kienle P; Nowak K; Kieser M; Slanger TE; Burmeister B; Kelsen D; Niedzwiecki D; Schuhmacher C; Urba S; van de Velde C; Walsh TN; Ychou M; Jensen K
    Eur J Surg Oncol; 2017 Aug; 43(8):1550-1558. PubMed ID: 28551325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction - a phase III trial of the German AIO/CAO-V/CAOGI.
    Al-Batran SE; Goetze TO; Mueller DW; Vogel A; Winkler M; Lorenzen S; Novotny A; Pauligk C; Homann N; Jungbluth T; Reissfelder C; Caca K; Retter S; Horndasch E; Gumpp J; Bolling C; Fuchs KH; Blau W; Padberg W; Pohl M; Wunsch A; Michl P; Mannes F; Schwarzbach M; Schmalenberg H; Hohaus M; Scholz C; Benckert C; Knorrenschild JR; Kanngießer V; Zander T; Alakus H; Hofheinz RD; Roedel C; Shah MA; Sasako M; Lorenz D; Izbicki J; Bechstein WO; Lang H; Moenig SP
    BMC Cancer; 2017 Dec; 17(1):893. PubMed ID: 29282088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perioperative chemotherapy vs. neoadjuvant chemoradiation in gastroesophageal junction adenocarcinoma : A population-based evaluation of the Munich Cancer Registry.
    Münch S; Habermehl D; Agha A; Belka C; Combs SE; Eckel R; Friess H; Gerbes A; Nüssler NC; Schepp W; Schmid RM; Schmitt W; Schubert-Fritschle G; Weber B; Werner J; Engel J
    Strahlenther Onkol; 2018 Feb; 194(2):125-135. PubMed ID: 29071366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perioperative chemotherapy versus postoperative chemoradiotherapy in patients with resectable gastric/gastroesophageal junction adenocarcinomas: A survival analysis of 5058 patients.
    Fitzgerald TL; Efird JT; Bellamy N; Russo SM; Jindal C; Mosquera C; Holliday EG; Biswas T
    Cancer; 2017 Aug; 123(15):2909-2917. PubMed ID: 28386965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-analysis of postoperative morbidity and perioperative mortality in patients receiving neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal and gastro-oesophageal junctional cancers.
    Kumagai K; Rouvelas I; Tsai JA; Mariosa D; Klevebro F; Lindblad M; Ye W; Lundell L; Nilsson M
    Br J Surg; 2014 Mar; 101(4):321-38. PubMed ID: 24493117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perioperative immune checkpoint inhibitors combined with chemotherapy versus chemotherapy for locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis of randomized controlled trials.
    Huang D; Sun F; Ke L; Li S
    Int Immunopharmacol; 2024 Sep; 138():112576. PubMed ID: 38941672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy for metastatic carcinoma of the esophagus and gastro-esophageal junction.
    Homs MY; v d Gaast A; Siersema PD; Steyerberg EW; Kuipers EJ
    Cochrane Database Syst Rev; 2006 Oct; (4):CD004063. PubMed ID: 17054195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma.
    Anderegg MCJ; van der Sluis PC; Ruurda JP; Gisbertz SS; Hulshof MCCM; van Vulpen M; Mohammed NH; van Laarhoven HWM; Wiezer MJ; Los M; van Berge Henegouwen MI; van Hillegersberg R
    Ann Surg Oncol; 2017 Aug; 24(8):2282-2290. PubMed ID: 28424936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Role of postoperative chemoradiotherapy in the therapeutic management of adenocarcinomas of the stomach and oesogastric junction].
    Ben Salah H; Bahri M; Dhouib F; Daoud J
    Cancer Radiother; 2016 Dec; 20(8):830-832. PubMed ID: 27793531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286).
    Hoeppner J; Lordick F; Brunner T; Glatz T; Bronsert P; Röthling N; Schmoor C; Lorenz D; Ell C; Hopt UT; Siewert JR
    BMC Cancer; 2016 Jul; 16():503. PubMed ID: 27435280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.